| Symbol | OCMLF |
|---|---|
| Name | ONCOSIL MED LTD. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | - |
| Address | 2113 Australia NSW Level 5, 7 Eden Park Drive |
| Telephone | +61 2 8935 9629 |
| Fax | — |
| — | |
| Website | https://www.oncosil.com/ |
| Incorporation | — |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | 6/30 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | International Reporting: ASX - Australian Securities Exchange |
| CIK | — |
| Description | OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. Additional info from OTC: |
No news found.